Bristol's Shares Take Hit From Cancer

Wall Street JournalBristol's Shares Take Hit From Cancer-Drug ResultsWall Street JournalAnalysts said the overall survival benefit was smaller than expected and the drug showed no significant benefit in a subgroup of patients—which could make Opdivo more vulnerable to competition from immune-boosting cancer drugs developed by Merck ...UPDATE 1-Bristol's Opdivo cuts risk of lung cancer death for someReutersNew Bristol-Myers drug improves survival for lung-cancer patientsCrain's New York BusinessBristol-Myers slumps as cancer drug trial results disappointsWorcester TelegramInvestor's Business Dailyall 59 news articles »

Share this post